Imaging software developer Median Technologies has been selected to provide imaging and services for six new clinical studies in oncology for a total of $6 million.
The trials are as follows:
- A phase III study for non-small cell lung cancer
- A phase III study for glioblastoma
- A phase III study for metastatic gastric adenocarcinoma
- A phase IB/II study for metastatic breast cancer
- A phase II study for myelofibrosis
- A phase IB/II study for kidney cancer
The studies are sponsored by U.S. biotech and pharmaceutical companies, Median said. It did not name the firms.
